Item 8.01. Other Events
On January 25, 2013, Depomed, Inc. ("Depomed"), Santarus, Inc. ("Santarus"),
Valeant International Bermuda ("Valeant") and Sun Pharma Global FZE, Sun
Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc.
(collectively, "Sun") entered into a settlement and license agreement (the
"Settlement Agreement") to resolve pending patent litigation involving
GlumetzaŽ (extended release metformin tablets) 1000 mg and 500 mg.
The Settlement Agreement grants Sun the right to begin selling a generic version
of Glumetza on August 1, 2016, or earlier under certain circumstances. The
Settlement Agreement is subject to review by the U.S. Department of Justice and
the Federal Trade Commission, as well as entry by the U.S. District Court for
the District of New Jersey of an order dismissing the litigation.
Add
DEPO to Portfolio
Set Alert
Email to a
Friend